Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing

Resistance of cancer cells to immune-mediated killing poses a significant challenge in optimizing therapeutic strategies and minimizing adverse effects during chemotherapy, radiotherapy, and immunotherapy. Consequently, exploring novel biomarkers are critically needed to assess and monitor cancer tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Nasraa, Mohamed H. (Author) , Riad, Mahmoud (Author) , Kirschfink, Michael (Author)
Format: Article (Journal)
Language:English
Published: 19 June 2025
In: Medical oncology
Year: 2025, Volume: 42, Issue: 7, Pages: 1-13
ISSN:1559-131X
DOI:10.1007/s12032-025-02832-z
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12032-025-02832-z
Get full text
Author Notes:Mohamed Hassan Nasraa, Mahmoud Mohamed Bahgat, Michael Kirschfinik

MARC

LEADER 00000caa a2200000 c 4500
001 1938686233
003 DE-627
005 20251120193550.0
007 cr uuu---uuuuu
008 251017s2025 xx |||||o 00| ||eng c
024 7 |a 10.1007/s12032-025-02832-z  |2 doi 
035 |a (DE-627)1938686233 
035 |a (DE-599)KXP1938686233 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Nasraa, Mohamed H.  |e VerfasserIn  |0 (DE-588)1379195799  |0 (DE-627)1938773179  |4 aut 
245 1 0 |a Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing  |c Mohamed Hassan Nasraa, Mahmoud Mohamed Bahgat, Michael Kirschfinik 
264 1 |c 19 June 2025 
300 |b Illustrationen 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 19. Juni 2025 
500 |a Gesehen am 17.10.2025 
520 |a Resistance of cancer cells to immune-mediated killing poses a significant challenge in optimizing therapeutic strategies and minimizing adverse effects during chemotherapy, radiotherapy, and immunotherapy. Consequently, exploring novel biomarkers are critically needed to assess and monitor cancer treatment response, detect toxic side effects early, and guide individualized therapy. We conducted this research to enhance our understand challenges posed by drug resistance in breast cancer treatment where the impact of pretreatment of BT-474 and SKBR-3 breast cancer cell lines with doxorubicin hydrochloride (doxorubicin) and paclitaxel (taxol) on complement-dependent cytotoxicity (CDC) and opsonization was opserveded. Both cell lines were treated with different concentrations of each drug for 24 and 48 h, followed by evaluating expression of membrane-bound complement regulatory proteins (mCRPs), factor H (fH) binding, iC3b opsonization, and cell killing by CDC. Pretreatment with chemotherapeutics led to variable upregulation of mCRPs (CD46, CD55, CD59) and increased fH binding, contributing to reduced cancer cell lysis at both time points. Conversely, iC3b opsonization was enhanced after 48 h of exposure to either drug. Though this work is limited to HER2-positive breast cancer cell lines, our data suggest that though this work is limited to HER2-positive breast cancer cell lines, short-term exposure to chemotherapeutics enhanced their resistance to CDC. However, since they are efficiently opsonized with the iC3b, this could increase their vulnerability to immunological attacks by CDCC) and ADCC. Such unique contribution illuminates a previously unnoticed shift in the immune elimination landscape following chemotherapy and opens doors for enhancing combination immunotherapies. 
650 4 |a Breast cancer BT-474 and SKBR-3 cells 
650 4 |a Chemotherapy 
650 4 |a Complement-dependent opsonization and cytotoxicity (CDC) 
650 4 |a Doxorubicin and taxol 
700 1 |a Riad, Mahmoud  |d 1969-  |e VerfasserIn  |0 (DE-588)123415616  |0 (DE-627)706291166  |0 (DE-576)293699682  |4 aut 
700 1 |a Kirschfink, Michael  |e VerfasserIn  |0 (DE-588)120927152  |0 (DE-627)080974457  |0 (DE-576)292452411  |4 aut 
773 0 8 |i Enthalten in  |t Medical oncology  |d New York, NY : Springer, 1984  |g 42(2025), 7, Artikel-ID 275, Seite 1-13  |h Online-Ressource  |w (DE-627)320468240  |w (DE-600)2008172-8  |w (DE-576)288571770  |x 1559-131X  |7 nnas  |a Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing 
773 1 8 |g volume:42  |g year:2025  |g number:7  |g elocationid:275  |g pages:1-13  |g extent:13  |a Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing 
856 4 0 |u https://doi.org/10.1007/s12032-025-02832-z  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20251017 
993 |a Article 
994 |a 2025 
998 |g 120927152  |a Kirschfink, Michael  |m 120927152:Kirschfink, Michael  |d 50000  |e 50000PK120927152  |k 0/50000/  |p 3  |y j 
999 |a KXP-PPN1938686233  |e 4789048942 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"19 June 2025"}],"id":{"doi":["10.1007/s12032-025-02832-z"],"eki":["1938686233"]},"name":{"displayForm":["Mohamed Hassan Nasraa, Mahmoud Mohamed Bahgat, Michael Kirschfinik"]},"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1984-","dateIssuedKey":"1984","publisher":"Springer ; Humana Press","publisherPlace":"New York, NY ; Totowa, NJ"}],"id":{"issn":["1559-131X"],"zdb":["2008172-8"],"eki":["320468240"]},"pubHistory":["1.1984 -"],"part":{"extent":"13","volume":"42","text":"42(2025), 7, Artikel-ID 275, Seite 1-13","issue":"7","pages":"1-13","year":"2025"},"note":["Gesehen am 15.04.14"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killingMedical oncology","recId":"320468240","language":["eng"],"title":[{"title_sort":"Medical oncology","title":"Medical oncology"}]}],"title":[{"title":"Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing","title_sort":"Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing"}],"person":[{"family":"Nasraa","given":"Mohamed H.","roleDisplay":"VerfasserIn","display":"Nasraa, Mohamed H.","role":"aut"},{"family":"Riad","given":"Mahmoud","roleDisplay":"VerfasserIn","display":"Riad, Mahmoud","role":"aut"},{"family":"Kirschfink","given":"Michael","roleDisplay":"VerfasserIn","display":"Kirschfink, Michael","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online veröffentlicht: 19. Juni 2025","Gesehen am 17.10.2025"],"recId":"1938686233","language":["eng"]} 
SRT |a NASRAAMOHACHEMOTHERA1920